Photo by Sharon McCutcheon on Pexels.com

Planet Green Holdings Stock Rose 331% Fueled By $10-Million Deal and Blue Gem

Planet Green Holdings Stock Rose 331 Percent Fueled by $50-Million Acquisition of 17.9 Blue Gem

By Glenford S. Robinson

Talk about a hyperbolic launch into space, Planet Green Holdings Corp. (NYSE: PLAG) did just that with its climactic rise into the stratosphere of 331% on Friday, launching from a day’s low of $2.85 to $11.51, with a trading volume of about 5.8 million shares as of 10:18 a.m. ET, compared with a 65-day average volume of 60,378.

So, what has caused such an amazing run? Well, it all comes down to the press release the company released on October 16, 2018. According to Benzinga, another reason for the climactic rise of PLAG is that Yulong Eco-Materials Ltd. (NASDAQ: YECO) rose more than 600 percent this past week after the company announced a $50-million acquisition deal for the millennium Sapphire, a 17.9 blue gem that was recently appraised at a value between $60 million and $90 million.

As a result of this deal, Yulong said it has decided to begin the process of spinning off its China business by moving its headquarters to New York, so the company can focus on its gemstone business. In addition, this Yulong news seemed to have drawn an increased amounts of trading volume into other U.S.-listed Chinese stocks, such as TDH Holdings (NASDAQ:PETZ), which rose 40.9 percent.

The press release stated that PLAG closed a private placement transaction deal with Yimin Jin, the Company’s chief strategy officer and director, and Hongxiang Yu, the company’s chairman.

The company received $10 million in exchange for 2.4 million shares of the company’s common stock, which represents a purchase price of approximately $4.25 per share. It was at the Company’s 2018 annual shareholders meeting that the transaction received approval.

Trading of the company’s stock (PLAG) is currently halted due to pending news and the anticipation of extremely high volatility at the time of writing this article (1:00 pm-2:41pm, ET; Friday, October 18, 2018.

Anyone wishing to trade this dangerous stock should consult with his or her own investment advisor.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved

Check Also

The Inverted Yield Curve as an Accurate Predictor of Recession

Based on our team's analysis, if you look at the 5-year versus the 2-year bond spread, the yield curve looks like it's in neutral territory; it's on its way to inverting, but that's still a while off.

Bitcoin at All-Time Lows: Time to Buy, Says Bitcoin Experts…

Bitcoin will mint new millionaires in 2019

What About the New 52-Week High Mark for a Stock?

For the short-term minded trader who elects to buy the stock as a result of its 52-week outstanding performance, short-term trouble could be on the horizon. The main reason why there could be trouble is because professional and institutional traders use a stock’s 52-week high mark has a take-profit point where they lock in their gains accrued over the past year.

Meridian Bioscience, Inc., Stock (VIVO) in Spot Light Today After FDA Granted Marketing Authorization of Alethia CMV Assay Test System to the Company

According to the Centers for Disease Control and Prevention, more than half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms of infection. However, CMV infection can cause serious health problems for people with weakened immune systems and for some newborns.

Fastest Way to Make Short-Term Profits in the Stock Market is Shorting Stocks

My discovery explains the reason why most traders lose money in the stock market. Those losing traders just approach the market the wrong way. First, one must understand that what goes up must come down to some degree because profit has to be made by traders. However, what goes down doesn’t necessarily mean that it will come back up at all. That is because companies do run out of business, which cause their stock prices to plummet without recovery.

SEC Settles Insider Trading Claims Against Former Chairman and CEO of Advanced Medical Optics

The SEC's complaint alleged that in October 2008 Mazzo executed a nondisclosure agreement with Abbott Laboratories, Inc., as Abbott explored a potential acquisition of AMO...

Pfizer Stock (PFE) on Investor Radar Today, Nov 23, 2018, After FDA Approval of Its Acute Myeloid Leukemia Drug Daurismo (glasdegib)

The FDA granted the approval of Daurismo to Pfizer...

%d bloggers like this: